Recent Developments and Future Directions in Adult Lower-grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2019 Feb 13

PMID 30753579

Citations 59

Authors

David Schiff

Martin van den Bent

Michael A Vogelbaum

Wolfgang Wick

C Ryan Miller

Martin Taphoorn

Whitney Pope

Paul D Brown

Michael Platten

Rakesh Jalali

Terri Armstrong

Patrick Y Wen

Affiliations

Soon will be listed here.

Abstract

The finding that most grades II and III gliomas harbor isocitrate dehydrogenase (IDH) mutations conveying a relatively favorable and fairly similar prognosis in both tumor grades highlights that these tumors represent a fundamentally different entity from IDH wild-type gliomas exemplified in most glioblastoma. Herein we review the most recent developments in molecular neuropathology leading to reclassification of these tumors based upon IDH and 1p/19q status, as well as the potential roles of methylation profiling and deletional analysis of cyclin-dependent kinase inhibitor 2A and 2B. We discuss the epidemiology, clinical manifestations, benefit of surgical resection, and neuroimaging features of lower-grade gliomas as they relate to molecular subtype, including advanced imaging techniques such as 2-hydroxyglutarate magnetic resonance spectroscopy and amino acid PET scanning. Recent, ongoing, and planned studies of radiation therapy and both cytotoxic and targeted chemotherapies are summarized, including both small molecule and immunotherapy approaches specifically targeting the mutant IDH protein.

Citing Articles

Clinical value of the promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment.

Darlix A, Bady P, Deverdun J, Lefort K, Rigau V, Le Bars E Neurooncol Adv. 2025; 7(1):vdae224.

PMID: 40041202 PMC: 11877643. DOI: 10.1093/noajnl/vdae224.

Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma.

Himstead A, Chen J, Chu E, Perez-Rosendahl M, Zheng M, Mathew S Biomedicines. 2025; 13(1).

PMID: 39857783 PMC: 11762706. DOI: 10.3390/biomedicines13010201.

Research Progress on Glioma Microenvironment and Invasiveness Utilizing Advanced Multi-Parametric Quantitative MRI.

Song D, Fan G, Chang M Cancers (Basel). 2025; 17(1.

PMID: 39796702 PMC: 11719598. DOI: 10.3390/cancers17010074.

The characteristics of auditorial event-related potential under propofol sedation associated with preoperative cognitive performance in glioma patients.

Wang X, Yang W, Jian M, Liang Y, Yang Z, Chen Y Front Neurosci. 2024; 18:1431406.

PMID: 39610867 PMC: 11603416. DOI: 10.3389/fnins.2024.1431406.

A Novel Mitochondrial-Related Gene Signature for the Prediction of Prognosis and Therapeutic Efficacy in Lower-Grade Glioma.

Yang J, Shen L, Zhou J, Wu J, Yue C, Wang T Biochem Genet. 2024; .

PMID: 39356352 DOI: 10.1007/s10528-024-10928-w.

References

de Leeuw C, Vogelbaum M . Supratotal resection in glioma: a systematic review. Neuro Oncol. 2018; 21(2):179-188. PMC: 6374756. DOI: 10.1093/neuonc/noy166. View

Pusch S, Krausert S, Fischer V, Balss J, Ott M, Schrimpf D . Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathol. 2017; 133(4):629-644. DOI: 10.1007/s00401-017-1677-y. View

Douw L, Klein M, Fagel S, van den Heuvel J, Taphoorn M, Aaronson N . Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009; 8(9):810-8. DOI: 10.1016/S1474-4422(09)70204-2. View

Wijnenga M, French P, Dubbink H, Dinjens W, Atmodimedjo P, Kros J . The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol. 2017; 20(1):103-112. PMC: 5761503. DOI: 10.1093/neuonc/nox176. View

Shankar G, Kirtane A, Miller J, Mazdiyasni H, Rogner J, Tai T . Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A. 2018; 115(36):E8388-E8394. PMC: 6130372. DOI: 10.1073/pnas.1805751115. View

Vogelbaum M, Jost S, Aghi M, Heimberger A, Sampson J, Wen P . Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2011; 70(1):234-43. DOI: 10.1227/NEU.0b013e318223f5a7. View

Jenkins R, Xiao Y, Sicotte H, Decker P, Kollmeyer T, Hansen H . A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet. 2012; 44(10):1122-5. PMC: 3600846. DOI: 10.1038/ng.2388. View

Burger P . What is an oligodendroglioma?. Brain Pathol. 2002; 12(2):257-9. PMC: 8095985. DOI: 10.1111/j.1750-3639.2002.tb00440.x. View

Laack N, Brown P, Ivnik R, Furth A, Ballman K, Hammack J . Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys. 2005; 63(4):1175-83. DOI: 10.1016/j.ijrobp.2005.04.016. View

10.

Vitucci M, Hayes D, Miller C . Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br J Cancer. 2010; 104(4):545-53. PMC: 3049580. DOI: 10.1038/sj.bjc.6606031. View

11.

Caseiras G, Chheang S, Babb J, Rees J, Pecerrelli N, Tozer D . Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting. Eur J Radiol. 2009; 73(2):215-20. DOI: 10.1016/j.ejrad.2008.11.005. View

12.

Sollmann N, Wildschuetz N, Kelm A, Conway N, Moser T, Bulubas L . Associations between clinical outcome and navigated transcranial magnetic stimulation characteristics in patients with motor-eloquent brain lesions: a combined navigated transcranial magnetic stimulation-diffusion tensor imaging fiber tracking.... J Neurosurg. 2017; 128(3):800-810. DOI: 10.3171/2016.11.JNS162322. View

13.

Ruda R, Bello L, Duffau H, Soffietti R . Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol. 2012; 14 Suppl 4:iv55-64. PMC: 3480244. DOI: 10.1093/neuonc/nos199. View

14.

van Kessel E, Baumfalk A, van Zandvoort M, Robe P, Snijders T . Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a systematic review of neurocognitive functioning prior to anti-tumor treatment. J Neurooncol. 2017; 134(1):9-18. PMC: 5543199. DOI: 10.1007/s11060-017-2503-z. View

15.

Taphoorn M, van den Bent M, Mauer M, Coens C, Delattre J, Brandes A . Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol. 2007; 25(36):5723-30. DOI: 10.1200/JCO.2007.12.7514. View

16.

Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E . Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol. 2007; 61(5):484-90. DOI: 10.1002/ana.21125. View

17.

Buckner J, Shaw E, Pugh S, Chakravarti A, Gilbert M, Barger G . Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016; 374(14):1344-55. PMC: 5170873. DOI: 10.1056/NEJMoa1500925. View

18.

Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F . Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol. 2016; 18(11):1529-1537. PMC: 5063521. DOI: 10.1093/neuonc/now133. View

19.

Cairncross G, MacDonald D, Ludwin S, Lee D, Cascino T, Buckner J . Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994; 12(10):2013-21. DOI: 10.1200/JCO.1994.12.10.2013. View

20.

Taal W, van der Rijt C, Dinjens W, Sillevis Smitt P, Wertenbroek A, Bromberg J . Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics. J Neurooncol. 2014; 121(2):365-72. DOI: 10.1007/s11060-014-1641-9. View